

### **ABSTRACT**





### **CLINICAL PERSPECTIVES:**

#### **What is new:**



#### **Abbreviations:**

- ANS: autonomic nervous system
- CABG: coronary artery bypass grafting
- 79 CaCl<sub>2</sub>: calcium chloride
- ChAT: choline acetyltransferase
- GP: ganglionated plexi
- MV: mitral valve
- NaCl: sodium chloride
- POAF: postoperative atrial fibrillation
- TH: tyrosine hydroxylase

### **INTRODUCTION**



#### **METHODS**

#### **Trial Design and oversight**



Adult patients referred for isolated MV repair or replacement for MR were eligible for enrollment. Exclusion criteria included: (1) adult patients >80 years of age, (2) history of persistent AF or persistent AF detected by 7-day Holter monitoring before surgery, (3) prior cardiac surgery, 4) poor compliance or inability to complete follow-up, (5) urgent cardiac surgery, (6) congenital heart disease, (7) significant mitral stenosis (MV orifice area  $\leq 2$  cm<sup>2</sup>), (8)



outcome assessment were blinded to randomization.

#### **Preoperative baseline data collection**

Prior to surgery, all patients with severe MR referred for MV surgery received 7-day 155 Holter monitoring with the capability of heart rate variability calculation.<sup>19</sup> Patients with a 156 history of persistent AF or had AF for  $\geq$ 7 days preoperatively were excluded from this study. The rest of the patients meeting the inclusion criteria were considered potential candidates.

#### **Intervention**

After MV repair or replacement, operators performed multi-point injection of 2 mL of 160  $5\%$  CaCl<sub>2</sub> or 0.9% NaCl into the four major atrial GP as previously described.<sup>19</sup> All the surgeons



After midterm analysis, to better understand the mechanisms underlying the contradictory 183 effect of  $Ca^{2+}$ -mediated autonomic denervation, 113 consecutive patients referred for CABG or MV surgery were screened. Forty patients meet the inclusion criteria of the CAPF-AF or CAP-AF2 trial (CABG, n=20; MV surgery, n=20) gave consent to allow investigators to take tissue



- **Immunohistochemistry studies**
- Immunohistochemistry of tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT)

193 was performed as previously describe.<sup>20</sup> Image analysis of nerve density and

immunohistochemistry staining was detected via ImageJ (Rawak Software Inc., Stuttgart,

- Germany). Quantitative analysis of the TH and ChAT expression in myocardial and ARGP
- 196 samples was determined by ELISA and Western blot as described before.<sup>20</sup>

#### **Statistical Analysis**

All analyses were based on the intention-to-treat principle including all patients who were randomized. For the primary outcome, Kaplan-Meier survival curves were used to describe the time-dependent incidence of POAF of both groups, the difference of which was compared by the log-rank test. Secondary outcomes were evaluated by Mann-Whitney U test, Chi-square test or Fisher's exact test. Data were reported as medians and quartiles (1st, 3rd quartile) for quantitative data and as numbers for qualitative data. For the heart rate variability (HRV) data requiring repeated measures, generalized estimating equations were used to test possible differences in HRV, assuming treatment and time since surgery as fixed factors, with marginal distribution and a first-order autoregressive correlation matrix to test the main and interaction effects. All analyses were conducted using the SPSS software (version 24.0) and R software version 4.1.3. All reported *P* values are two-sided; significant level is 0.05. *P* values and 95% confidence intervals presented in this report have not been adjusted for multiplicity; therefore, inferences drawn from these statistics should be interpreted with caution.

#### **RESULTS**



#### **Primary Outcome:**

229 Midterm analysis revealed that the POAF incidence was higher in the  $CaCl<sub>2</sub>$  group (55.13%) than that in the NaCl group (37.80%; see results below). The research oversight 231 committee determined that  $CaCl<sub>2</sub>$  injection caused harm and terminated the trial. All the analyses 232 therefore only included the 160 patients enrolled prior to the midterm analysis (78 and 82) 233 patients in the CaCl<sub>2</sub> and NaCl group, respectively). All 160 patients stayed in the hospital for  $\geq$ 7 days; there was no missing data. POAF occurred during the first 7 days after surgery in 31 of 82

235 patients  $(37.80\%)$  in the NaCl group and 43 of 78 patients  $(55.13\%)$  in the CaCl<sub>2</sub> group  $(95\%)$ 

- confidence interval of difference: 1.01%-32.48%, *P*= 0.028) (**Figure 1B**). The Kaplan-Meier curve also illustrates separation of the two curves on postoperative day 3 when the occurrence of POAF typically reaches its peak (**Figure 1C**). The median of the first episode of POAF occurred 239 37.3 (28.1, 48.9) hours after surgery in the NaCl group and 41.5 hours (33.0, 56.9) in the CaCl<sub>2</sub> group (*P*=0.132). All patients with AF received subcutaneous enoxaparin injection until
- discharge.

#### **Secondary Outcomes and AF-related measurements**

The median length of hospitalization and ICU stay were not different between the two 244 groups (**Table 2**). When POAF occurred, more patients in the CaCl<sub>2</sub> group were hospitalized  $\geq$ 7 245 days after surgery  $(69.8\% \text{ vs. } 45.2\%, P=0.033)$ . Patients in the CaCl<sub>2</sub> group had more episodes of 246 POAF ( $p=0.007$ ) but with similar AF burden. The average ventricular rate in POAF as well as the number of patients with POAF>24 hours or >48 hours were not different between the two 248 groups, either. More patients in the CaCl<sub>2</sub> group required amiodarone to treat POAF, which was 249 determined by clinicians when POAF lasted longer than 30 minutes. Plasma levels of hs-CRP and IL-6 on postoperative day 1 and 3 were not different between the two groups. Two patients in each group required cardioversion for hemodynamic compromise. The time-domain measurements as well as the frequency domain measurements of HRV such as low frequency (LF) power, high frequency (HF) power and the LF/HF ratio were not different between the two groups (**Online Figure 1**). The frequency of PACs, couplets and nonsustained atrial tachycardia was not different between the two groups on each postoperative day (**Online Figure 2**) as well.

**Adverse effects and complications** 

To prevent adverse effects such as significant bradycardia (heart rate <40 bpm) as 258 described in the CAP-AF trial,  $CaCl<sub>2</sub>$  and NaCl were slowly injected into each GP to avoid pressure buildup inside the GP. No significant bradycardia (<40 bpm) was noticed in any patient.



Western blot (**Online Figure 3**). The extent of fibrosis in the atrial myocardium adjacent to the anterior right GP was not different between the two groups **(Online Figure 4**).

#### **DISCUSSION**

288 The main finding of the CAP-AF2 trial is that  $Ca^{2+}$ -mediated autonomic denervation unexpectedly increased the incidence of POAF in patients with MR without persistent AF, contradictory to the results of the CAP-AF trial that only recruited patients receiving isolated CABG. In the CAP-AF2 trial, atrial bigeminy, couplets or NSAT immediately preceded the 292 initiation of POAF in the CaCl<sub>2</sub> group but not the NaCl group. Immunohistochemistry studies demonstrated different autonomic substrates between patients with MR and ischemic heart disease. A lower ratio of TH/ChAT in the anterior right GP and adjacent myocardium in the former suggests parasympathetic dominance at the tissue level; a higher TH/ChAT ratio in the 296 latter suggests sympathetic dominance.  $Ca^{2+}$ -mediated autonomic denervation therefore exerts contradictory effects on the incidence of POAF on patients receiving MV surgery vs. CABG. 298 Multiple preclinical studies of MR-related AF have demonstrated similar findings.<sup>22-27</sup> First, the atrial effective period was prolonged with significant heterogeneity. Second, moderate but heterogeneous interstitial fibrosis existed. Third, atrial conduction velocity was reduced and often heterogeneous. Fourth, inflammatory cell infiltration of atrial myocardium was observed. Fifth, malfunction of major metabolic pathways occurred in patients with MR and was further augmented by β-adrenergic stimulation. Improvement of metabolic derangement mitigated AF. Although spontaneous AF was rarely reported by these studies, AF could easily be induced by electrical stimulation, indicating that in the presence of appropriate triggers, AF can be initiated and maintained by the aforementioned AF substrates. In the present study, patients with persistent AF were excluded. The study population therefore represents one in which MR was

severe enough that already created a substrate for AF but without appropriate triggers to initiate AF. Parasympathetic dominance at the tissue level may be protective in patients with severe MR. 310 Disturbance of the cardiac autonomic balance by  $Ca^{++}$ -mediate autonomic denervation provided the triggers to initiate POAF as illustrated in **Figure 2A.**

In patients with paroxysmal AF without significant structural heart diseases, AF episodes are commonly preceded by co-activation of the sympathetic and parasympathetic nervous systems.  $10,12,28$  However, exaggerated sympathetic activity is the hallmark of AF initiation. In the majority of patients including those with structural heart diseases, AF episodes are usually preceded by an increased low-frequency component of HRV, a marker of sympathetic hyperactivity.<sup>28</sup> Preclinical studies on ambulatory animals also indicated that paroxysmal AF and AT were invariably preceded by activation of the intrinsic cardiac ANS evidenced by rapid 319 discharges recorded from the GP and ligament of Marshall.<sup>11,29</sup> Although the paroxysmal AF or AT episodes were also accompanied by co-activation of the extrinsic cardiac ANS, such as vagus nerve and stellate ganglion, 20-25% of the episodes of paroxysmal AT or AF were not preceded by activation of the vagus nerve or stellate ganglion, indicating that the intrinsic cardiac ANS (e.g. GP) plays an indispensable role in the initiation of paroxysmal AF or AT. Moreover, PACs were typically preceded by a surge of sympathetic nerve activity; most of the paroxysmal  $\rm AF$  or AT episodes followed a larger and more sustained surge of sympathetic nerve activity.<sup>11,30</sup> The average activity of the intrinsic cardia ANS, evidenced by direct neural recording of GP, also strongly correlated with the PAC burden in patients after cardiac surgery.<sup>30</sup>

In the CAP-AF2 trial, POAF was preceded by frequent atrial bigeminy, couplets or NSAT in only 9/31 (29.0%) patients in the NaCl group, in contrast to 33/43 (76.7%) patients in 330 the CaCl<sub>2</sub> group. That is, CaCl<sub>2</sub>-mediated autonomic denervation altered the POAF initiation pattern from sinus rhythm with a single PAC to frequent bigeminy, couplets or NSAT, possibly resulting from shifting the sympathetic-parasympathetic balance (**Figure 2**). As discussed before,

PACs and paroxysmal AT are often preceded by a surge of sympathetic nerve activity. Immunohistochemistry data revealed parasympathetic dominance at the tissue level (both GP 335 and atrial myocardium) in patients receiving MV surgery.  $Ca^{2+}$ -mediated autonomic denervation likely injured more parasympathetic than sympathetic neural elements, which tipped the balance toward sympathetic dominance. As a result, frequent atrial bigeminy, couplets or NSAT  $\alpha$  occurred, eventually initiating POAF. Of note, in the CAP-AF trial, Ca<sup>2+</sup>-mediated autonomic denervation suppressed PACs and NSAT but did not affect the initiation pattern of POAF. We hypothesize that a higher sympathetic state is also critical in POAF initiation in patients 341 undergoing CABG.  $Ca^{2+}$ -mediated autonomic denervation mitigated higher tissue sympathetic activity, evidence by less frequent complex PACs and NSAT. Additionally, HRV showed diminished HF and LF components but preserved LF/HF ratio,<sup>19</sup> suggesting that the sympathetic-parasympathetic balance was not perturbed by autonomic denervation thereby not altering the 345 initiation pattern of POAF. Therefore, for patients in the CaCl<sub>2</sub> group of the CAP-AF trial, if autonomic denervation failed to overcome the higher sympathetic activity, POAF was triggered by similar mechanisms as seen in the NaCl group. Based on the contradictory results in the CAP-AF and CAP-AF2 trials, perturbation of the autonomic balance can be beneficial or harmful, depending on the underlying substrate.

An important lesson learned from the two CAP-AF trials is that autonomic remodeling and perhaps other remodeling processes may vary greatly among different cardiovascular diseases, leading to differential effects on POAF when cardiac ANS is perturbed. If the CAP-AF2 trial had recruited both MV surgery and CABG populations, the results might have been neural; the harm to the MV surgery population would have not been exposed. Future studies on the pathogenesis or therapies of AF, not limited to POAF, may need to focus on a relatively homogeneous population and avoid a study population including multiple cardiovascular diseases. For example, the  $AFACT<sup>31</sup>$  trial randomized patients to surgical PVI vs. surgical



#### **Study Limitation**

First, we did not directly record the neural activity of the GP; the activity of the intrinsic cardiac ANS was therefore deduced from expression of TH and ChAT in the anterior right GP and adjacent myocardium. In addition, the postoperative HRV was inconclusive likely due to a smaller-than-expected sample size resulting from premature termination of the trial. The interpretation that higher sympathetic activity preceded POAF was therefore based on published pre-clinical and clinical studies. Second, we do not have immunohistochemical data on normal controls to compare tissue autonomic innervation among normal controls, patients with MR and patients with ischemic heart disease. Therefore, sympathetic and parasympathetic dominance described in this study only represents the comparison between the MR and CABG populations. Third, for logistical reasons, only the anterior right GP and adjacent myocardium were sampled. Tissue autonomic innervation and fibrosis may not be generalized to the entire atrial neural network and myocardium. Fourth, only five of 160 patients were found to have paroxysmal AF based on history and 7-day Holter monitoring prior to surgery. The prevalence of paroxysmal AF



#### **REFERENCES:**

- 1. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation:
- mechanisms, manifestations and management. Nat Rev Cardiol 2019;16:417-36.
- 2. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of
- postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation

2002;106:75-80.

- 3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial
- fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
- 4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014
- AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of
- the American College of Cardiology/American Heart Association Task Force on Clinical
- Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:104-32.
- 5. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of
- Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair:
- PAPABEAR: a randomized controlled trial. Jama 2005;294:3093-100.
- 6. Ardell JL, Andresen MC, Armour JA, et al. Translational neurocardiology: preclinical models
- and cardioneural integrative aspects. J Physiol 2016;594:3877-909.
- 7. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the
- epicardiac neural ganglionated subplexuses in the human heart. Anat Rec 2000;259:353-82.
- 8. Ardell JL, Armour JA. Neurocardiology: Structure-Based Function. Compr Physiol

2016;6:1635-53.

- 9. Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic
- nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of
- atrial fibrillation. J Am Coll Cardiol 2007;50:61-8.

- 10. Lombardi F, Tarricone D, Tundo F, Colombo F, Belletti S, Fiorentini C. Autonomic nervous
- system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes
- before, during and after paroxysmal atrial fibrillation. Eur Heart J 2004;25:1242-8.
- 11. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and
- paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008;118:916-25.
- 12. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial
- fibrillation. Circulation 2002;105:2753-9.
- 13. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by
- in vitro autonomic nerve stimulation. Heart Rhythm 2005;2:624-31.
- 14. Patterson E, Lazzara R, Szabo B, et al. Sodium-calcium exchange initiated by the Ca2+
- transient: an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol 2006;47:1196-206.
- 15. Po SS, Nakagawa H, Jackman WM. Localization of left atrial ganglionated plexi in patients
- with atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:1186-9.
- 16. Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary
- vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol
- 2013;62:2318-25.
- 17. Peunova N, Enikolopov G. Amplification of calcium-induced gene transcription by nitric
- oxide in neuronal cells. Nature 1993;364:450-3.
- 18. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration
- in excitotoxicity. Cell Calcium 2003;34:325-37.
- 19. Wang H, Zhang Y, Xin F, et al. Calcium-Induced Autonomic Denervation in Patients With
- Post-Operative Atrial Fibrillation. J Am Coll Cardiol 2021;77:57-67.
- 20. Zhao J, Zhang Y, Yin Z, et al. Impact of proinflammatory epicardial adipose tissue and
- differentially enhanced autonomic remodeling on human atrial fibrillation. J Thorac Cardiovasc
- Surg 2022.

- 21. Wang H, Han J, Wang Z, et al. A prospective randomized trial of the cut-and-sew Maze
- procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac
- Cardiovasc Surg 2018;155:608-17.
- 22. Everett TH 4th, Verheule S, Wilson EE, Foreman S, Olgin JE. Left atrial dilatation resulting
- from chronic mitral regurgitation decreases spatiotemporal organization of atrial fibrillation in
- left atrium. Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2452-60.
- 23. Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J.Alterations in atrial
- electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral
- regurgitation. Circulation. 2003 May 27;107(20):2615-22.
- 24. Everett TH 4th, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial
- remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a
- comparison in canine models of structural and electrical atrial remodeling.
- Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2911-23.
- 25. Tang M, Zhang S, Sun Q, Huang C. Alterations in Electrophysiology and Tissue Structure of
- the Left Atrial Posterior Wall in a Canine Model of Atrial Fibrillation Caused by Chronic Atrial
- Dilatation. Circ J 2007:71:1636-1642.
- 26. Monti LD, Lucotti PC, Setola E et al. Effects of chronic elevation of atrial natriuretic peptide
- and free fatty acid levels in the induction of type 2 diabetes mellitus and insulin resistance in
- patients with mitral valve disease. Nutr Metab Cardiovasc Dis. 2012 Jan;22(1):58-65.
- 27. Oikawa S, Kai Y, Mano A, et al. Non-neuronal cardiac acetylcholine system playing
- indispensable roles in cardiac homeostasis confers resiliency to the heart. J Physiol Sci. 2021 Jan 18;71(1):2.

- 28. Carnagarin R, Kiuchi MG, Ho JK, Matthews VB, Schlaich MP. Sympathetic Nervous
- System Activation and Its Modulation: Role in Atrial Fibrillation. Front Neurosci 2018;12:1058.
- 29. Choi EK, Shen MJ, Han S, et al. Intrinsic cardiac nerve activity and paroxysmal atrial
- tachyarrhythmia in ambulatory dogs. Circulation 2010;121:2615-23.
- 30. Shen MJ, Coffey AC, Straka S, et al. Simultaneous recordings of intrinsic cardiac nerve
- activity and skin sympathetic nerve activity from human patients during the postoperative period.
- Heart Rhythm 2017;14:1587-93.
- 31. Driessen AHG, Berger WR, Krul APJ, van den Berg NWE, Neefs J, Piersma FR, Yin
- 479 DRPPCP<sup>2</sup>, de Jong JSSG<sup>3</sup>, van Boven WP, de Groot JR<sup>.</sup> Ganglion Plexus Ablation in Advanced
- Atrial Fibrillation: The AFACT Study. J Am Coll Cardiol. 2016 Sep 13;68(11):1155-1165.
- 32. Pokushalov E, Kozlov B, Romanov A, et al. Botulinum toxin injection in epicardial fat pads
- can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot
- study. J Am Coll Cardiol 2014;64:628-9.
- 33. Waldron NH, Cooter M, Haney JC, et al. Temporary autonomic modulation with botulinum
- toxin type A to reduce atrial fibrillation after cardiac surgery. Heart Rhythm 2019;16:178-84.

#### **FIGURE LEGENDS**



*p*<0.01; \*\*\*: *p*<0.001.

#### 508

#### 507 **Table 1. Demographic and Clinical Characteristics at Baseline**



Values are median (1st, 3rd quartile), or n (percentage). AF= atrial fibrillation; ALT = alanine transaminase; AST = aspartate transaminase; BNP = brain natriuretic peptide; CAD: coronary artery disease; EF = ejection fraction; FS = Fraction shortening; COPD = chronic obstructive 512 pulmonary disease; hsCRP = high-sensitivity C-reaction protein; IL-6 = interleukin-6; MI =

513 history of myocardial infarction; pNN50 = percentage of RR intervals that differ by > 50 ms;

514 rMSSD =root-mean-square of successive RR interval difference; SDNN = SD of normal-to-

515 normal interval; NSAT=non-sustained atrial tachyarrhythmia. \*: Calculated by chi-square test.

516 Others: calculated by Mann-Whitney *U* test.

#### 518 **Table 2. Secondary outcomes and peri-operative conditions**



519 Values are median (1st, 3rd quartile) or n (percentage). POD: postoperative day. All

520 abbreviations identical to Table 1. \*Calculated by chi-square test. †Calculated by Fisher exact

521 test. Others: calculated by Mann-Whitney *U* test.

- 523 **Figure 1. Trial design and primary outcome. A. Flow diagram of trial design.** A total of 884
- 524 patients were screened. Up to the midterm analysis, 160 patients consented to participate.
- 525 Participants were 1:1 randomized to CaCl<sub>2</sub> injection and NaCl injection. **B.** Cumulative
- 526 incidence of POAF over 7 days after surgery. **C.** Kaplan-Meier curve of POAF. HR: hazard
- 527 ratio. CI: 95% confidence interval.



529

### Figure 1B.



## Figure 1C.



- 533 **Figure 2. The most common pattern of POAF initiation in the CAP-AF2 trial. A.** POAF was
- 534 preceded by frequent atrial bigeminy, couplets or nonsustained AT in the CaCl<sub>2</sub> group **B.** A
- 535 single PAC (red arrow) initiated POAF in the NaCl group.



**POAF** 

# Figure 2B.



537

- 539 **Figure 3. Tissue autonomic innervation.** Tissue samples obtained from patients undergoing
- 540 coronary artery bypass surgery (CABG, n=20) or mitral valve surgery (MVS, n=20) for mitral
- 541 regurgitation. **A-C.** Percentage of the area in the anterior right ganglionated plexi stained
- 542 positive for choline acetyltransferase (ChAT; **A**) or tyrosine hydroxylase (TH, **B**) as well as the
- 543 TH/ChAT ratio (**C**). **D-F.** ChAT staining, TH staining and TH/ChAT ratio of autonomic nerves.
- 544 **G-I.** Quantitative analysis by ELISA of TH and ChAT expression. **D-I.** Tissue samples obtained
- 545 from atrial myocardium adjacent to the anterior right ganglionated plexi. GP.  $\cdot$   $\cdot$   $p$  < 0.05;  $\cdot$   $\cdot$   $\cdot$
- 546 *p*<0.01; \*\*\*: *p*<0.001.

Figure 3.



